SCHEMBL6357072

SCHEMBL6357072

CC(C)C(C(=O)O)N(CC(=O)c1ccccc1)C(=O)c1ccc(Cl)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 4/20 0.44
NPSR1 Q6W5P4 3/20 0.44
CYP1A2 P05177 2/20 0.44
CYP3A4 P08684 2/20 0.44
CYP2C9 P11712 2/20 0.44
CYP2C19 P33261 2/20 0.44
LMNA P02545 2/20 0.44
HTT P42858 2/20 0.44
TSHR P16473 1/20 0.44
MAPK1 P28482 1/20 0.44
MAPT P10636 3/20 0.43
L3MBTL1 Q9Y468 3/20 0.43
CXCR3 P49682 1/20 0.42
CES2 O00748 1/20 0.41
CES1 P23141 1/20 0.41
KMT2A Q03164 2/20 0.40
MEN1 O00255 1/20 0.40
HPGD P15428 1/20 0.40
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6358298 0.92 TSHR (0.42) POLBNPSR1CYP3A4LMNAHTT
SCHEMBL6359362 0.92 TSHR (0.42) POLBNPSR1CYP3A4LMNAHTT
SCHEMBL6350477 0.85 L3MBTL1 (0.51) NPSR1CYP1A2CYP3A4CYP2C9CYP2C19
SCHEMBL6349879 0.84 ALDH1A1 (0.49) CYP1A2CYP3A4CYP2C9CYP2C19TSHR
SCHEMBL6358289 0.83 ALDH1A1 (0.49) POLBNPSR1LMNAMAPK1MAPT
SCHEMBL6350864 0.81 TRPM8 (0.47) CYP3A4LMNAMAPK1MAPTL3MBTL1
SCHEMBL6359179 0.81 TRPM8 (0.47) CYP3A4LMNAMAPK1MAPTL3MBTL1
SCHEMBL6349361 0.80 ALDH1A1 (0.45) CYP3A4LMNATSHRMAPK1MAPT
SCHEMBL6350978 0.80 ALDH1A1 (0.45) CYP3A4LMNATSHRMAPK1MAPT
SCHEMBL6356051 0.80 ALDH1A1 (0.45) CYP3A4LMNATSHRMAPK1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6960575-B2 For use as inhibitors of chymase SANTEN PHARMACEUTICAL CO., LTD. (JP) 2005-11-01 US disclosed
US-20040097496-A1 Novel thiazine derivatives SANTEN PHARMACEUTICAL CO.,LTD. (JP) 2004-05-20 US disclosed
US-6713472-B1 2-OXO-1,2,3,4-TETRAHYDROPYRAZINE DERIVATIVES; CHYMASE INHIBITORS SANTEN PHARMACEUTICAL CO., LTD. (JP) 2004-03-30 US disclosed
EP-1211249-A1 NOVEL THIAZINE OR PYRAZINE DERIVATIVES SANTEN PHARMACEUTICAL CO., LTD. (JP) 2002-06-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040097496-A1 Novel thiazine derivatives CMA1, TPSD1, HRH4 POLB 3917/4885NPSR1 428/4885CYP1A2 634/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.